D57.434
Sickle-cell thalassemia beta zero with dactylitis
Clinical Classification Guidelines
Medical Intelligence & Overview
Sickle-cell thalassemia beta zero with dactylitis is a complex blood disorder characterized by the presence of abnormal hemoglobin in red blood cells, leading to chronic anemia and episodes of painful swelling in the fingers and toes. This condition combines elements of sickle-cell disease and thalassemia, resulting in a unique set of symptoms and health challenges. The term 'beta zero' indicates a specific genetic mutation resulting in the absence of normal beta-globin chains in hemoglobin. Dactylitis, or inflammation of the fingers and toes, is a common initial manifestation, especially in young children. Managing this condition involves a comprehensive approach to reduce symptoms and prevent complications.
Causes & Symptoms
Clinical Causes: Genetic mutations affecting hemoglobin production, inherited from parents Presence of the sickle hemoglobin (HbS) gene combined with thalassemia genes Beta zero mutations leading to the absence of beta-globin chains in hemoglobin Inheritance pattern following autosomal recessive transmission, requiring both parents to pass on defective genes
Key Symptoms: Dactylitis (painful swelling of fingers and toes) Chronic anemia, leading to fatigue and weakness Jaundice (yellowing of the skin and eyes) Frequent infections due to spleen dysfunction Delayed growth and development in children episodes of pain crisis affecting various parts of the body Hand-foot syndrome characterized by swelling and pain
Diagnostic & Treatment
Diagnosis Path: Diagnosis involves a combination of laboratory tests and genetic studies. Initial confirmation includes blood tests such as a complete blood count (CBC) revealing anemia, and hemoglobin electrophoresis or high-performance liquid chromatography (HPLC) to identify abnormal hemoglobin variants. Genetic testing can determine specific mutations associated with sickle-cell thalassemia beta zero. Additionally, imaging studies may be used to assess organ involvement if complications are suspected. Early diagnosis is crucial for effective management and improving quality of life.
Treatment Protocols: Management strategies focus on alleviating symptoms, preventing complications, and maintaining overall health. Common approaches include: - Regular blood transfusions to reduce sickle-cell crisis and iron overload - Use of hydroxyurea to decrease the frequency of pain episodes - Pain management during crises - Antibiotics and vaccines to prevent infections - Folic acid supplementation to support red blood cell production - Monitoring for organ damage through regular health check-ups - Bone marrow transplant in select cases, which may offer a potential cure - Supportive care such as nutritional counseling, psychological support, and physiotherapy It is important for individuals with this condition to have ongoing medical care and personalized treatment plans.
Clinical Advice & FAQs
Billing Guidance
Is D57.434 a billable ICD-10 code?
Yes, D57.434 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report D57.434?
Clinical documentation must specify the nature of Sickle-cell thalassemia beta zero with dactylitis and any associated comorbidities for accurate reporting.
Cite this Clinical Reference